Alexander DeLuca, M.D.
Addiction, Pain, & Public Health website  
[Home] [Library]  [Slides]  [Search]  [Medline]  [Links]
Statement of Purpose; Privacy policy; Email Confidentiality Policy; Statements of Ownership & Sponsorship; Advertising policy

Acamprosate Enhances N-Methyl-D-Apartate Receptor-Mediated Neurotransmission But Inhibits Presynaptic GABAB Receptors in Nucleus Accumbens Neurons. [Abstract]

by Berton F, Francesconi WG, Madamba SG, Zieglgansberger W, Siggins GR; Alcohol Clin Exp Res; 22(1):183-91 ; Feb 1998.  Originally posted: 8/21/2004; [www.doctordeluca.com/Library/AddictionMeds/AcampEnhancesNMDA04.htm].

[Print version]

Acamprosate (calcium acetylhomotaurine) is used therapeutically in Europe to reduce relapse in weaned alcoholics. However, the mechanisms of acamprosate action in the central nervous system are still obscure, although early studies suggested an action on GABA receptors. The nucleus accumbens (NAcc) is a brain region thought to underlie ethanol reinforcement. Recent studies from our laboratory have demonstrated that ethanol inhibits both N-methyl-D-aspartate (NMDA) and non-NMDA types of glutamatergic synaptic transmission in the NAcc.

In the present study, we used voltage- and current-clamp intracellular recording of NAcc core neurons in a slice preparation to examine acamprosate actions on resting membrane properties and pharmacologically isolated synaptic responses. We isolated NMDA and non-NMDA receptor-mediated excitatory postsynaptic potentials or currents (EPSP/Cs) with 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) and DL-2-amino-5-phosphonovalerate (d-APV), respectively. Bicuculline was also included to block GABAA receptors. Superfusion of acamprosate (5, 50, and 300 [mu]M) did not alter the resting membrane properties of NAcc neurons. However, 300 [mu]M acamprosate significantly increased the NMDA receptor-mediated components of EPSP/Cs (NMDA-EPSP/Cs) with recovery on washout. In contrast, 300 [mu]M acamprosate had no significant effect on the non-NMDA receptor component of the EPSP/Cs (non-NMDA-EPSP/Cs).

To test acamprosate actions on the GABA system, we superfused 60 [mu]M d-APV and 20 [mu]M CNQX to block glutamatergic transmission and evoked monosynaptic GABAA receptor-mediated synaptic responses within the NAcc. Acamprosate (300 [mu]M) did not change these monosynaptic GABAA-IPSCs. We also used a paired-pulse paradigm to test whether acamprosate could act on presynaptic GABAB autoreceptors, in the presence of d-APV and CNQX to block glutamatergic transmission. Like 0.5 [mu]M CGP 34358 (a GABAB receptor blocker), acamprosate significantly decreased the paired-pulse inhibition (PPI) of GABAA-IPSCs at short interstimulus intervals (ISIs).

Thus, acamprosate may concomitantly enhance NMDA-EPSP/Cs while blocking presynaptic GABAB receptor-mediated inhibition of GABA release. These results suggest that acamprosate's clinical efficacy in preventing relapse in weaned alcoholics could derive from its interactions with both the glutamatergic and GABAergic systems in the NAcc.

 [Top of Page]


[END]

 

Addiction, Pain, and Public Health website

Alexander DeLuca, M.D.

[Top of Page]

Originally posted:  8/20/2004

All website Email to:   adeluca@doctordeluca.com 

Statement of Purpose; Privacy policy; Email Confidentiality Policy; Statements of Ownership & Sponsorship; Advertising policy

Most recently revised: 8/21/2004
Copyright 1999 - 2004; All rights reserved.